Clinical Trial Update: GA-68 DOTA-TOC of Somatostatin Positive Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for GA-68 DOTA-TOC targeting somatostatin receptors in neuroendocrine tumors and related malignancies, with terminated status an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroblastoma
• Neuroendocrine Tumor
• Paraganglioma

Drugs mentioned

• GA-68 DOTA-TOC (GA-68 DOTA-TOC)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neuroendocrine Tumor, Paraganglioma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-11-12